Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ib/II open-label study of intravesical TARA-002 in high-grade non-muscle invasive bladder cancer in adults
CTR20261484Phase 2Active
- Sponsor
- Protara Therapeutics
- Start
- Apr 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of TARA-002 in bladder cancer, Bladder cancer in situ (CIS), sponsored by Protara Therapeutics. Started Apr 2026; status: active.
02
Drugs
TARA-002
03
Conditions
bladder cancerBladder cancer in situ (CIS)
Beyond the preview
Go deeper on CTR20261484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261484.